Published in Biochim Biophys Acta on February 01, 2010
Multi-dimensional mass spectrometry-based shotgun lipidomics and novel strategies for lipidomic analyses. Mass Spectrom Rev (2011) 2.39
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30
Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev (2011) 1.93
Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One (2013) 1.36
Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol (2011) 1.06
A reversed-phase capillary ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) method for comprehensive top-down/bottom-up lipid profiling. Anal Bioanal Chem (2012) 1.03
Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods (2012) 0.98
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Novel advances in shotgun lipidomics for biology and medicine. Prog Lipid Res (2015) 0.95
Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis (2012) 0.91
Lipidomics for studying metabolism. Nat Rev Endocrinol (2016) 0.91
Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers. Int J Mol Sci (2013) 0.90
Phloretin ameliorates 2-chlorohexadecanal-mediated brain microvascular endothelial cell dysfunction in vitro. Free Radic Biol Med (2012) 0.88
Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease. ScientificWorldJournal (2012) 0.88
Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease. Front Physiol (2013) 0.88
Peroxisomes in brain development and function. Biochim Biophys Acta (2015) 0.88
Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. J Alzheimers Dis (2012) 0.84
Sphingolipids and ceramides in human aqueous humor. Mol Vis (2013) 0.82
Enhanced selectivity for sulfatide by engineered human glycolipid transfer protein. Structure (2011) 0.82
Lipidomics of glycosphingolipids. Metabolites (2012) 0.80
A comparison of trabecular meshwork sphingolipids and ceramides of ocular normotensive and hypertensive states of DBA/2J mice. J Ocul Pharmacol Ther (2013) 0.79
Comprehensive untargeted lipidomic analysis using core-shell C30 particle column and high field orbitrap mass spectrometer. J Chromatogr A (2016) 0.79
Advanced Shotgun Lipidomics for Characterization of Altered Lipid Patterns in Neurodegenerative Diseases and Brain Injury. Methods Mol Biol (2016) 0.78
Potential Adverse Effects of Prolonged Sevoflurane Exposure on Developing Monkey Brain: From Abnormal Lipid Metabolism to Neuronal Damage. Toxicol Sci (2015) 0.78
Sphingolipids and ceramides of mouse aqueous humor: Comparative profiles from normotensive and hypertensive DBA/2J mice. Biochimie (2014) 0.77
Selective deuterium labeling of the sphingoid backbone: facile syntheses of 3,4,5-trideuterio-d-erythro-sphingosine and 3-deuterio-d-erythro-sphingomyelin. Chem Phys Lipids (2010) 0.77
Embedding Aβ42 in heterogeneous membranes depends on cholesterol asymmetries. Biophys J (2013) 0.77
Comparative lipidomics of mouse brain exposed to enriched environment. J Lipid Res (2013) 0.77
Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Med (2012) 0.77
Lipidomic analysis of cerebrospinal fluid by mass spectrometry-based methods. J Inherit Metab Dis (2014) 0.76
Covalent adduct formation between the plasmalogen-derived modification product 2-chlorohexadecanal and phloretin. Biochem Pharmacol (2015) 0.76
Human trabecular meshwork sphingolipid and ceramide profiles and potential latent fungal commensalism. Invest Ophthalmol Vis Sci (2014) 0.76
Lipidomics for precision medicine and metabolism: A personal view. Biochim Biophys Acta (2017) 0.75
Off-line mixed-mode liquid chromatography coupled with reversed phase high performance liquid chromatography-high resolution mass spectrometry to improve coverage in lipidomics analysis. Anal Chim Acta (2016) 0.75
The Effects of Long-Term Saturated Fat Enriched Diets on the Brain Lipidome. PLoS One (2016) 0.75
Shotgun lipidomics in substantiating lipid peroxidation in redox biology: Methods and applications. Redox Biol (2017) 0.75
Hippocampal lipid differences in Alzheimer's disease: a human brain study using matrix-assisted laser desorption/ionization-imaging mass spectrometry. Brain Behav (2016) 0.75
MALDI Orbitrap Mass Spectrometry Profiling of Dysregulated Sulfoglycosphingolipids in Renal Cell Carcinoma Tissues. J Am Soc Mass Spectrom (2017) 0.75
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 13.54
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol (2001) 8.88
Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med (2006) 6.15
Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev (2005) 5.98
LRP: a multifunctional scavenger and signaling receptor. J Clin Invest (2001) 5.31
Electrospray mass spectrometry of phospholipids. Mass Spectrom Rev (2003) 4.18
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 3.61
Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci (1996) 3.26
Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J Lipid Res (2003) 3.18
Quantitative analysis and molecular species fingerprinting of triacylglyceride molecular species directly from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry. Anal Biochem (2001) 3.09
Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem (2002) 2.45
Automated lipid identification and quantification by multidimensional mass spectrometry-based shotgun lipidomics. Anal Chem (2009) 2.44
Shotgun lipidomics: multidimensional MS analysis of cellular lipidomes. Expert Rev Proteomics (2005) 2.23
Toward fingerprinting cellular lipidomes directly from biological samples by two-dimensional electrospray ionization mass spectrometry. Anal Biochem (2004) 2.17
Electrospray ionization mass spectroscopic analysis of human erythrocyte plasma membrane phospholipids. Proc Natl Acad Sci U S A (1994) 2.12
Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration (1996) 2.09
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci (2008) 2.09
Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med (2004) 2.06
Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.04
Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem (2001) 1.98
Alzheimer disease. JAMA (2002) 1.95
Quantitative determination of phospholipid compositions by ESI-MS: effects of acyl chain length, unsaturation, and lipid concentration on instrument response. J Lipid Res (2001) 1.92
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. J Mol Neurosci (2004) 1.76
Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm (Vienna) (2000) 1.73
Shotgun lipidomics of cardiolipin molecular species in lipid extracts of biological samples. J Lipid Res (2006) 1.73
Microfluidics-based electrospray ionization enhances the intrasource separation of lipid classes and extends identification of individual molecular species through multi-dimensional mass spectrometry: development of an automated high-throughput platform for shotgun lipidomics. Rapid Commun Mass Spectrom (2008) 1.72
A possible role for plasmalogens in protecting animal cells against photosensitized killing. J Biol Chem (1988) 1.66
Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol (2004) 1.64
Liquid chromatography/mass spectrometry of phospholipids using electrospray ionization. Anal Chem (1994) 1.61
Neurobiological bases of age-related cognitive decline in the rhesus monkey. J Neuropathol Exp Neurol (1996) 1.57
Factors influencing the electrospray intrasource separation and selective ionization of glycerophospholipids. J Am Soc Mass Spectrom (2006) 1.54
Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl (2000) 1.54
Tandem mass spectrometry in the study of fatty acids, bile acids, and steroids. Mass Spectrom Rev (2003) 1.52
Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids (2000) 1.51
Alterations in lipid homeostasis of mouse dorsal root ganglia induced by apolipoprotein E deficiency: a shotgun lipidomics study. J Neurochem (2007) 1.51
Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia (2006) 1.49
Sphingomyelinases: enzymology and membrane activity. FEBS Lett (2002) 1.49
Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem (1994) 1.38
Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res (2001) 1.31
Lipidomics is emerging. Biochim Biophys Acta (2003) 1.31
Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest (1997) 1.31
Shotgun lipidomics of phosphoethanolamine-containing lipids in biological samples after one-step in situ derivatization. J Lipid Res (2005) 1.28
Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age Ageing (2006) 1.24
Alkaline methanolysis of lipid extracts extends shotgun lipidomics analyses to the low-abundance regime of cellular sphingolipids. Anal Biochem (2007) 1.22
Metabolic and functional aspects of sulfogalactolipids. Biochim Biophys Acta (1994) 1.19
Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2005) 1.19
Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics. J Neurochem (2007) 1.18
Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. J Biol Chem (2002) 1.18
MALDI-TOF MS in lipidomics. Front Biosci (2007) 1.16
Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res (1995) 1.14
Abundance of triacylglycerols in ganglia and their depletion in diabetic mice: implications for the role of altered triacylglycerols in diabetic neuropathy. J Neurochem (2006) 1.10
Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol (1999) 1.07
Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell Mol Biol (Noisy-le-grand) (2003) 1.07
Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Curr Alzheimer Res (2006) 1.07
Alzheimer's disease: beta-Amyloid protein and tau. J Neurosci Res (2002) 1.06
Systematic analysis of choline-containing phospholipids using multi-dimensional mass spectrometry-based shotgun lipidomics. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.02
Galactolipids are molecular determinants of myelin development and axo-glial organization. Biochim Biophys Acta (2002) 1.01
Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med (2002) 1.01
The protective role of plasmalogens in iron-induced lipid peroxidation. Free Radic Biol Med (1999) 0.99
Acid sphingomyelinase-derived ceramide signaling in apoptosis. Subcell Biochem (2002) 0.97
Will caloric restriction and folate protect against AD and PD? Neurology (2003) 0.97
Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm (Vienna) (2003) 0.96
The role of apolipoprotein E in lipid metabolism in the central nervous system. Cell Mol Life Sci (2004) 0.95
The biological significance of plasmalogens in defense against oxidative damage. Exp Gerontol (1998) 0.94
Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease. Neurobiol Aging (2008) 0.94
New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. Nat Med (1996) 0.94
Sulfatide storage in neurons causes hyperexcitability and axonal degeneration in a mouse model of metachromatic leukodystrophy. J Neurosci (2007) 0.94
LDL receptor-related protein (LRP) in Alzheimer's disease: towards a unified theory of pathogenesis. Microsc Res Tech (2000) 0.93
Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp Gerontol (2006) 0.91
Lipoproteins and lipid peroxidation in Alzheimer's disease. J Nutr Health Aging (2003) 0.89
Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry (2002) 0.87
Monoclonal antibody to embryonic CNS antigen A2B5 provides evidence for the involvement of membrane components at sites of Alzheimer degeneration and detects sulfatides as well as gangliosides. J Neurochem (1989) 0.87
Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. Curr Med Chem (2006) 0.86
LRP in Alzheimer's disease: friend or foe? J Clin Invest (2000) 0.85
Membrane instability, plasmalogen content, and Alzheimer's disease. J Neurochem (1998) 0.85
Plasmalogen-selective phospholipase A2 and its involvement in Alzheimer's disease. Biochem Soc Trans (1998) 0.84
Possible link between lipid metabolism and cerebral amyloid angiopathy in Alzheimer's disease: A role for high-density lipoproteins? Haemostasis (1999) 0.83
Subcellular distribution, molecular dynamics and catabolism of plasmalogens in myocardium. Mol Cell Biochem (1989) 0.82
Is the LDL receptor involved in cortical amyloid protein clearance? Neurochem Res (2006) 0.78
Aluminium and Alzheimer's disease: review of possible pathogenic mechanisms. Dementia (1996) 0.78
Effects of human apolipoprotein E isoforms on the amyloid beta-protein concentration and lipid composition in brain low-density membrane domains. J Neurochem (2007) 0.76